Tolerability and Safety of CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients With Cardio Renal Syndrome With Severe Renal Impairment

Study Overview
=================
Brief Summary
-----------------
Renal failure is present in 40% of heart failure patients, and is one of the main comorbidities of heart failure. Follow-up with pulmonary artery pressure (PAP) monitoring has shown a reduction in mortality and frequency of hospitalization in patients with heart failure alone in the CHAMPION trial. Patients with New York Heart Association class III heart failure and a hospitalization in the previous 12 months were included in that study. They benefited from the CardioMEMS™ HF device with a sensor implanted in the pulmonary artery to measure PAP. According to that study, the information led to more precise and early adaptation of therapy by avoiding the onset of heart failure symptoms and reducing the number of hospitalizations. However, in that study, patients with impaired renal function (Glomerular Filtration Rate<25 mL/min/1.73m2) were excluded, limiting the indication for treatment in those patients, and the evolution of renal function during the study was not reported. Patients with heart failure AND advanced renal failure are defined as having a cardio-renal syndrome, with strong interaction between these 2 organs. In the event of predominant right heart failure, they may require treatment by renal replacement or dialysis. There seems to be a link between high venous pressure, renal repercussions and the need for dialysis. Additional follow-up data in this clinical situation are needed to confirm this link and to suggest the interest of continuous PAP monitoring to improve the management of these patients with cardio-renal syndrome with severe renal impairment defined by a Glomerular Filtration Rate< 30 ml/min/1.73m2 (KDIGO Cardio-renal 2019). This pilot study aims to evaluate how tolerable the CARDIOMEMS™ HF device in patients with cardio-renal syndrome and obtain the first information on the relationship between cardiac hemodynamics and renal function in this population.

Detailed Description
-----------------
There are currently 1.5 million heart failure patients in France. The high morbidity and mortality make it a major public health issue. Renal failure, present in 40% of these patients, is one of the main comorbidities of heart failure and makes its management more complex. Medical follow-up with pulmonary artery pressure (PAP) monitoring has shown a reduction in mortality and frequency of hospitalization in patients with heart failure alone in the CHAMPION trial. Patients with New York Heart Association class III heart failure and a hospitalization in the previous 12 months were included in this study. They benefited from the CardioMEMS™ HF device with implantation of a sensor in the pulmonary artery allowing direct and continuous measurement of PAP. According to this study, this information allowed for more precise and early adaptation of therapy by avoiding the occurrence of heart failure symptoms and reducing the frequency of hospitalizations. In this study, patients with impaired renal function were excluded (Glomerular Filtration Rate <25 mL/min/1.73m2), limiting the indication for treatment in these patients, and the evolution of renal function during the study was not reported. Patients with heart failure associated with advanced renal failure are defined as having a cardio-renal syndrome, with a strong interaction between these 2 organs that may, in particular in the case of predominant right heart failure, require treatment by renal replacement or dialysis. According to the data available to date, the predominant hypothesis is a link between high venous pressure, renal repercussions and the need for dialysis. Additional follow-up data in this clinical situation are needed to confirm this link and to suggest the interest of continuous monitoring of PAP to improve the management of these patients with cardio-renal syndrome with severe renal impairment defined by a Glomerular Filtration Rate< 30 ml/min/1.73m2 (KDIGO Cardio-renal 2019). Therefore, the investigators wish to initiate a pilot study evaluating the tolerability of the CARDIOMEMS™ HF device in patients with cardio renal syndrome and obtain the first information on the relationship between cardiac hemodynamics and renal function in this population. This is the first pilot study on the safety and tolerability of the use of the CardioMEMS™ HF medical device in cardio renal syndrome with severe renal impairment (documented by Glomerular Filtration Rate < 30 mL/min/1.73m2 measured by Iohexol clearance) treated medically and without renal replacement therapy. In this study, the CARDIOMEMS™ HF device, the most successful implanted pulmonary arterial pressure monitoring system currently available on the market will be implemented. Its teletransmitted information can guide the treatment of patients with heart failure.This system, by responding to the recent international recommendations which advocate a better understanding of the hemodynamic situation in this pathology with in particular the link between pulmonary arterial pressure and renal function, could help us to identify innovative evaluation tools with a view to improving therapeutic management with the new treatments available in heart failure (AA House et al: HF in kidney disease: a KDIGO conference report).

Official Title
-----------------
Evaluation of the Tolerability and Safety of the CARDIOMEMS™ Intracardiac Continuous Cardiac Hemodynamic Monitoring Device in Patients With Cardio Renal Syndrome With Severe Renal Impairment

Conditions
-----------------
Heart Failure, Renal Insufficiency

Intervention / Treatment
-----------------
* Device: Implantation of the CARDIOMEMS™ HF device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with class NYHA III heart failure having been hospitalized in the previous 12 months for cardiac decompensation (the current indication for the CARDIOMEMS™ system), right heart failure or biventricular heart failure with the definition of TAPSE<15mm and/or SDTI<9.5cm/s regardless of LVEF, NtproBNP>1500 pg/ml. Patient with advanced renal failure with GFR (CKD-EPI) < 30 ml/min/1.73m2 for more than 3 months confirmed by GFR measurement (Iohexol clearance) Patient with a pulmonary artery greater than 7 mm in diameter. The patient has been informed of the study set-up, objectives, constraints and patient rights. The patient must have given free and informed consent and signed the consent form. The patient must be affiliated or a beneficiary of a health insurance plan. Precautions: if the patient is on anticoagulant therapy, an International Normalized Ratio <1.5 is recommended before right heart catheterization and any implantation procedure Exclusion Criteria: Patients with a contraindication to the CARDIOMEMS™ HF system (pulmonary embolism with sequelae, artery less than 7 mm, active infection). Patients already on renal replacement therapy. Patients with a history of acute venous thrombosis. Patients unable to tolerate right heart catheterization. Patients with a major cardiovascular event (i.e., myocardial infarction, stroke) within 2 months of the initial examination. Patients with congenital heart disease or mechanical right heart valve(s). Patients with known hypersensitivity or allergy to aspirin and/or clopidogrel. Patients with a body mass index >35. Measure the patient's chest circumference at the armpit: if the patient's chest circumference is > 165 cm, the sensor should not be implanted. Patients unable to take dual anti-platelet therapy or anticoagulant therapy for one month after implantation Patient hypersensitive or allergic to iohexol. Patient is participating in another Class I interventional study, or has participated in another interventional study within the last 3 months. Patient is in an exclusion period determined by a previous study. Patient is under guardianship, conservatorship, or conservatorship. The patient refuses to sign the consent form. It is impossible to give the patient informed information. The patient is pregnant or nursing.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Intervention Model: Single Group Assignment
Interventional Model Description: Patients will be pre-selected (pre-inclusion visit) during hospitalizations in the cardiology and nephrology departments of the Nîmes University Hospital. The study will be offered to any patient with class NYHA III heart failure who has been hospitalized in the previous 12 months for cardiac decompensation (current indication for the CARDIOMEMS™ system) and with advanced chronic renal failure with GFR (CKD-EPI) < 30 ml/min/1.73m2 persisting for more than 3 months and confirmed by Iohexol clearance.
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: CARDIOMEMS(TM) HF device<br>Renal failure patients testing the CARDIOMEMS(TM) HF device | Device: Implantation of the CARDIOMEMS™ HF device<br>* The initial routine workup includes a nephrological evaluation: mGFR with Iohexol before fitting the CARDIOMEMS™ HF device, renal echo-Doppler, urinary sedimentation, etiological assessment of severe Chronic Kidney Disease, NT-ProBNP, impedancemetry, urinary ionogram, weight, anemia assessment, and correction of possible iron and/or vitamin deficiency and a cardiology evaluation: blood pressure, heart rate, clinical data, biology (Complete Blood Count, iono, urea, creatinine, total bilirubin, ferritin, CST), echocardiography (Left Ventricle Ejection Fraction, E/A, E/e', indexed volume of the left atrium, Tricuspid Annular Plane Systolic Excursion, Tissue Doppler S-wave, surface area of the right atrium, Systolic Pulmonary Artery Pressure, Right Atrial Pressure). The device will be implanted in the selected patients by Pr François Roubille at Montpellier University Hospital within 1 month of the pre-inclusion visit. It will monitor their pulmonary artery pressure.<br>* Other names: Nephrolocical evaluation measured with the CARDIOMEMS™ HF device;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse events | Perioperative collection of complications related to the puncture site (hematoma, arteriovenous fistula) and right catheterization (arrhythmia, peri-procedure heart failure decompensation). | On the day of implanting the Cardiomems device | 
| Adverse events | Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | One month after implanting the Cardiomems device | 
| Adverse events | Perioperative collection of complications related to the puncture site (hematoma, arteriovenous fistula) and right catheterization (arrhythmia, peri-procedure heart failure decompensation). Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | Two months after implanting the Cardiomems device | 
| Adverse events | Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | Three months after implanting the Cardiomems device | 
| Adverse events | Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | Four months after implanting the Cardiomems device | 
| Adverse events | Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | Five months after implanting the Cardiomems device | 
| Adverse events | Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | Six months after implanting the Cardiomems device | 
| Adverse events | Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | Seven months after implanting the Cardiomems device | 
| Adverse events | Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | Eight months after implanting the Cardiomems device | 
| Adverse events | Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | Nine months after implanting the Cardiomems device | 
| Adverse events | Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | Ten months after implanting the Cardiomems device | 
| Adverse events | Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | Eleven months after implanting the Cardiomems device | 
| Adverse events | Monthly collection of adverse events over the 12-month follow-up period. In particular, cardiac parameters will be collected (sensor failure, migration, re-calibration, re-intervention, gas embolism, allergic reaction, abnormal heart rate or rhythm, bleeding, hematoma, chest pain, nausea, vascular accident, infection, sepsis, delayed healing, atrial dysrhythmia clot formation, ecchymosis, vascular trauma, valve damage, pulmonary infarction, pulmonary embolism, heart attack (myocardial infarction), death, hemoptysis, separation of sensor and delivery system impossible) and renal (risk of infection, thrombotic risk, interference with dialysis catheter placement). | Twelve months after implanting the Cardiomems device | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Estimated effect on renal function | The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min | Between 1 day to 1 month before implanting the device. | 
| Measured effect on renal function | The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min. | Between 1 day to 1 month before implanting the device. | 
| Estimated effect on renal function | The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min | Day 0 (day of implanting the device) | 
| Measured effect on renal function | The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min. | Day 0 (day of implanting the device) | 
| Estimated effect on renal function | The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min | Month 3 | 
| Measured effect on renal function | The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min. | Month 3 | 
| Estimated effect on renal function | The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min | Month 6 | 
| Measured effect on renal function | The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min. | Month 6 | 
| Estimated effect on renal function | The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min | Month 9 | 
| Measured effect on renal function | The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min. | Month 9 | 
| Estimated effect on renal function | The estimated Glomerular Filtration Rate (eGFR) will be recorded in mL/min. | Month 12 | 
| Measured effect on renal function | The Glomerular Filtration Rate measured with Iohexol (mGFR) will be recorded in mL/min. | Month 12 | 
| Re-hospitalizations | Any re-hospitalizations will be recorded for a period of up to 12 months of follow-up | Month 12 | 
| Vital status | Patient dead or alive | Month 12 | 
| Link between cardiac hemodynamics and renal function: Pulmonary Arterial Pressure | Pulmonary Arterial Pressure will be continuously monitored for 12 months by the CardioMEMS™ HF intracardiac device in patients with severe cardio-renal syndrome and measured in Hg. | From Day 0 (day of implanting the device) to the end of Month 12 | 
| Link between cardiac hemodynamics and renal function: Glomerular Filtration Rate | Glomerular Filtration Rate will be measured by measuring plasma clearance of iohexol from a single sample. | Day 0 | 
| Link between cardiac hemodynamics and renal function: Pulmonary Arterial Pressure | Pulmonary Arterial Pressure will be continuously monitored for 12 months by the CardioMEMS™ HF intracardiac device in patients with severe cardio-renal syndrome and measured in Hg. Readings will be recorded at 3-monthly intervals. | Month 3 | 
| Link between cardiac hemodynamics and renal function: Glomerular Filtration Rate | Glomerular Filtration Rate will be measured in ml/min/1.72² by measuring plasma clearance of iohexol from a single sample. | Month 3 | 
| Link between cardiac hemodynamics and renal function: Pulmonary Arterial Pressure | Pulmonary Arterial Pressure will be continuously monitored for 12 months by the CardioMEMS™ HF intracardiac device in patients with severe cardio-renal syndrome and measured in Hg. Readings will be recorded at 3-monthly intervals. | Month 6 | 
| Link between cardiac hemodynamics and renal function: Glomerular Filtration Rate | Glomerular Filtration Rate will be measured in ml/min/1.72² by measuring plasma clearance of iohexol from a single sample. | Month 6 | 
| Link between cardiac hemodynamics and renal function: Pulmonary Arterial Pressure | Pulmonary Arterial Pressure will be continuously monitored for 12 months by the CardioMEMS™ HF intracardiac device in patients with severe cardio-renal syndrome and measured in Hg. Readings will be recorded at 3-monthly intervals. | Month 9 | 
| Link between cardiac hemodynamics and renal function: Glomerular Filtration Rate | Glomerular Filtration Rate will be measured in ml/min/1.72² by measuring plasma clearance of iohexol from a single sample. | Month 9 | 
| Link between cardiac hemodynamics and renal function: Pulmonary Arterial Pressure | Pulmonary Arterial Pressure will be continuously monitored for 12 months by the CardioMEMS™ HF intracardiac device in patients with severe cardio-renal syndrome and measured in Hg. Readings will be recorded at 3-monthly intervals. | Month 12 | 
| Link between cardiac hemodynamics and renal function: Glomerular Filtration Rate | Glomerular Filtration Rate will be measured in ml/min/1.72² by measuring plasma clearance of iohexol from a single sample. | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: exertional dyspnea | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. To quantify dyspnea, the patient is asked to indicate on a visual analog scale the point corresponding to his/her own perception, evaluated as the distance from the zero extreme (non dyspnea) and expressed as a percentage of the total length of the line. | Day 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: exertional dyspnea | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. To quantify dyspnea, the patient is asked to indicate on a visual analog scale the point corresponding to his/her own perception, evaluated as the distance from the zero extreme (non dyspnea) and expressed as a percentage of the total length of the line. | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: exertional dyspnea | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. To quantify dyspnea, the patient is asked to indicate on a visual analog scale the point corresponding to his/her own perception, evaluated as the distance from the zero extreme (non dyspnea) and expressed as a percentage of the total length of the line. | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: exertional dyspnea | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. To quantify dyspnea, the patient is asked to indicate on a visual analog scale the point corresponding to his/her own perception, evaluated as the distance from the zero extreme (non dyspnea) and expressed as a percentage of the total length of the line. | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: exertional dyspnea | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. To quantify dyspnea, the patient is asked to indicate on a visual analog scale the point corresponding to his/her own perception, evaluated as the distance from the zero extreme (non dyspnea) and expressed as a percentage of the total length of the line. | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: NT-pro-BNP biomarkers | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Natriuretic Peptide Tests (BNP, NT-proBNP) will be made on a single blood sample. BNP and NT-proBNP will be measured as percentages. | Day 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: NT-pro-BNP biomarkers | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Natriuretic Peptide Tests (BNP, NT-proBNP) will be made on a single blood sample. BNP and NT-proBNP will be measured in %. | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: NT-pro-BNP biomarkers | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Natriuretic Peptide Tests (BNP, NT-proBNP) will be made on a single blood sample. BNP and NT-proBNP will be measured as percentages. | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: NT-pro-BNP biomarkers | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Natriuretic Peptide Tests (BNP, NT-proBNP) will be made on a single blood sample. BNP and NT-proBNP will be measured as percentages. | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: NT-pro-BNP biomarkers | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Natriuretic Peptide Tests (BNP, NT-proBNP) will be made on a single blood sample. BNP and NT-proBNP will be measured as percentages. | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: left ventricular ejection fraction | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Left Ventricular Ejection Fraction will be measured as a percentage via the formula EF=SV/EDV (ejection fraction = stroke volume/end diastolic volume. | Day 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: left ventricular ejection fraction | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Left Ventricular Ejection Fraction will be measured as a percentage via the formula EF=SV/EDV (ejection fraction = stroke volume/end diastolic volume. | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: left ventricular ejection fraction | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Left Ventricular Ejection Fraction will be measured as a percentage via the formula EF=SV/EDV (ejection fraction = stroke volume/end diastolic volume. | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: left ventricular ejection fraction | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Left Ventricular Ejection Fraction will be measured as a percentage via the formula EF=SV/EDV (ejection fraction = stroke volume/end diastolic volume. | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: left ventricular ejection fraction | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Left Ventricular Ejection Fraction will be measured as a percentage via the formula EF=SV/EDV (ejection fraction = stroke volume/end diastolic volume. | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/A | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/A will be measured as a ratio. | Month 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/A | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/A will be measured as a ratio (the E/A ratio is the ratio of the early (E) to late (A) ventricular filling velocities). | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/A | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/A will be measured as a ratio (the E/A ratio is the ratio of the early (E) to late (A) ventricular filling velocities). | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/A | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/A will be measured as a ratio (the E/A ratio is the ratio of the early (E) to late (A) ventricular filling velocities). | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/A | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/A will be measured as a ratio (the E/A ratio is the ratio of the early (E) to late (A) ventricular filling velocities). | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/e' | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/e' will be measured as a ratio. | Month 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/e' | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/e' will be measured as a ratio (E= early diastolic transmitral flow velocity and e' = early diastolic mitral annular velocity). | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/e' | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/e' will be measured as a ratio (E= early diastolic transmitral flow velocity and e' = early diastolic mitral annular velocity). | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/e' | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/e' will be measured as a ratio (E= early diastolic transmitral flow velocity and e' = early diastolic mitral annular velocity). | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: E/e' | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. E/e' will be measured as a ratio (E= early diastolic transmitral flow velocity and e' = early diastolic mitral annular velocity). | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Indexed left atrial volume | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Indexed left atrial volume will be measured in ml/m2. | Month 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Indexed left atrial volume | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Indexed left atrial volume will be measured in ml/m2. | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Indexed left atrial volume | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Indexed left atrial volume will be measured in ml/m2. | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Indexed left atrial volume | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Indexed left atrial volume will be measured in ml/m2. | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Indexed left atrial volume | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Indexed left atrial volume will be measured in ml/m2. | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tricuspid Annular Plane Systolic Excursion | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tricuspid Annular Plane Systolic Excursion will be measured in cm. | Month 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tricuspid Annular Plane Systolic Excursion | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tricuspid Annular Plane Systolic Excursion will be measured in cm. | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tricuspid Annular Plane Systolic Excursion | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tricuspid Annular Plane Systolic Excursion will be measured in cm. | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tricuspid Annular Plane Systolic Excursion | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tricuspid Annular Plane Systolic Excursion will be measured in cm. | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tricuspid Annular Plane Systolic Excursion | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tricuspid Annular Plane Systolic Excursion will be measured in cm. | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tissue Doppler S-wave | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tissue Doppler S-wave will be measured in mV | Month 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tissue Doppler S-wave | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tissue Doppler S-wave will be measured in mV | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tissue Doppler S-wave | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tissue Doppler S-wave will be measured in mV | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tissue Doppler S-wave | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tissue Doppler S-wave will be measured in mV | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Tissue Doppler S-wave | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Tissue Doppler S-wave will be measured in mV | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrium area | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrium area will be measured in cm2. | Month 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrium area | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrium area will be measured in cm2. | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrium area | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrium area will be measured in cm2. | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrium area | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrium area will be measured in cm2. | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrium area | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrium area will be measured in cm2. | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Systolic pulmonary artery pressure | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Systolic pulmonary artery pressure will be measured in mmHg. | Month 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Systolic pulmonary artery pressure | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Systolic pulmonary artery pressure will be measured in mmHg. | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Systolic pulmonary artery pressure | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Systolic pulmonary artery pressure will be measured in mmHg. | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Systolic pulmonary artery pressure | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Systolic pulmonary artery pressure will be measured in mmHg. | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Systolic pulmonary artery pressure | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Systolic pulmonary artery pressure will be measured in mmHg. | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrial pressure | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrial pressure will be measured in mmHg. | Month 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrial pressure | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrial pressure will be measured in mmHg. | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrial pressure | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrial pressure will be measured in mmHg. | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrial pressure | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrial pressure will be measured in mmHg. | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Right atrial pressure | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Right atrial pressure will be measured in mmHg. | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Stroke volume | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV) will be measured and recorded in millilitres per square metre (ml/m2). | Day 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Stroke volume | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV) will be measured and recorded in millilitres per square metre (ml/m2). | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Stroke volume | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV) will be measured and recorded in millilitres per square metre (ml/m2). | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Stroke volume | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV) will be measured and recorded in millilitres per square metre (ml/m2). | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Stroke volume | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV) will be measured and recorded in millilitres per square metre (ml/m2). | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Heart rate | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. The patient's heart rate (HR) will be measured and recorded as beats per minute (BPM). | Day 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Heart rate | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. The patient's heart rate (HR) will be measured and recorded as beats per minute (BPM). | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Heart rate | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. The patient's heart rate (HR) will be measured and recorded as beats per minute (BPM). | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Heart rate | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. The patient's heart rate (HR) will be measured and recorded as beats per minute (BPM). | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: Heart rate | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. The patient's heart rate (HR) will be measured and recorded as beats per minute (BPM). | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: cardiac output | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Cardiac output (CO) will be measured and recorded in liters per minute. | Day 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: cardiac output | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Cardiac output (CO) will be measured and recorded in liters per minute. | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: cardiac output | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Cardiac output (CO) will be measured and recorded in liters per minute. | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: cardiac output | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Cardiac output (CO) will be measured and recorded in liters per minute. | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: cardiac output | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Cardiac output (CO) will be measured and recorded in liters per minute. | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: ventricular ejection time | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Ventricular ejection time (VET) will be measured and recorded in milliseconds. | Day 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: ventricular ejection time | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Ventricular ejection time (VET) will be measured and recorded in milliseconds. | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: ventricular ejection time | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Ventricular ejection time (VET) will be measured and recorded in milliseconds. | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: ventricular ejection time | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Ventricular ejection time (VET) will be measured and recorded in milliseconds. | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: ventricular ejection time | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Ventricular ejection time (VET) will be measured and recorded in milliseconds. | Month 12 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: pre-ejection period | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV), heart rate (HR), cardiac output (CO) ventricular ejection time (VET) and pre-ejection period (PER) will all be measured and recorded in milliseconds. | Day 0 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: pre-ejection period | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV), heart rate (HR), cardiac output (CO) ventricular ejection time (VET) and pre-ejection period (PER) will all be measured and recorded in milliseconds. | Month 3 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: pre-ejection period | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV), heart rate (HR), cardiac output (CO) ventricular ejection time (VET) and pre-ejection period (PER) will all be measured and recorded in milliseconds. | Month 6 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: pre-ejection period | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV), heart rate (HR), cardiac output (CO) ventricular ejection time (VET) and pre-ejection period (PER) will all be measured and recorded in milliseconds . | Month 9 | 
| Comparison of cardiac hemodynamic monitoring data with the clinical picture: pre-ejection period | The cardiac hemodynamic monitoring data will be compared with the clinical picture (exertional dyspnea, peak VO2 max) and currently available assessment tools (NT-pro-BNP biomarkers, echocardiography, impedancemetry) recorded in the electronic case report form. Stroke volume (SV), heart rate (HR), cardiac output (CO) ventricular ejection time (VET) and pre-ejection period (PER) will all be measured and recorded in milliseconds. | Month 12 | 
| Patient quality of life | The patient's quality of life will be evaluated using the EQ-5D questionnaire. This questionnaire essentially consists of two pages: the EQ-5D descriptive system (page 2 of the questionnaire) and the EQ-5D visual analog scale (EQ VAS) (page 3 of the questionnaire) ranging from 0 - 100 in which 0 = extremely bad health and 100 = excellent health. EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument. The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. | Day 0 | 
| Patient quality of life | The patient's quality of life will be evaluated using the EQ-5D questionnaire. This questionnaire essentially consists of two pages: the EQ-5D descriptive system (page 2 of the questionnaire) and the EQ-5D visual analog scale (EQ VAS) (page 3 of the questionnaire) ranging from 0 - 100 in which 0 = extremely bad health and 100 = excellent health. EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument. The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. | Month 3 | 
| Patient quality of life | The patient's quality of life will be evaluated using the EQ-5D questionnaire. This questionnaire essentially consists of two pages: the EQ-5D descriptive system (page 2 of the questionnaire) and the EQ-5D visual analog scale (EQ VAS) (page 3 of the questionnaire) ranging from 0 - 100 in which 0 = extremely bad health and 100 = excellent health. EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument. The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. | Month 6 | 
| Patient quality of life | The patient's quality of life will be evaluated using the EQ-5D questionnaire. This questionnaire essentially consists of two pages: the EQ-5D descriptive system (page 2 of the questionnaire) and the EQ-5D visual analog scale (EQ VAS) (page 3 of the questionnaire) ranging from 0 - 100 in which 0 = extremely bad health and 100 = excellent health. EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument. The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. | Month 9 | 
| Patient quality of life | The patient's quality of life will be evaluated using the EQ-5D questionnaire. This questionnaire essentially consists of two pages: the EQ-5D descriptive system (page 2 of the questionnaire) and the EQ-5D visual analog scale (EQ VAS) (page 3 of the questionnaire). EQ-5D is not an abbreviation and is the correct term to use when referring to the instrument. The EQ-5D descriptive system comprises five dimensions: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression. The EQ -5D is scored from 0 -100 and the VAS is scored from 0 -10. | Month 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Renal insufficiency,, heart failure,, medical device, blood pressure monitoring, tolerance